Global Gabapentin
Global Gabapentin

Gabapentin Comprehensive Study by End Products (Capsule, Tablet, Solution, Suspension), Distribution Channel (Online Distribution Channel, Offline Distribution Channel), End Use (Adult (Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome), Pediatric (Epilepsy)) Players and Region - Global Market Outlook to 2024

Gabapentin Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Feb 2020 Edition 225 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

The global Gabapentin market is expected to witness high demand due to increasing healthcare expenditure in the forecasted period. Gabapentin is an anti-epileptic drug, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. Dosage is based on medical condition and response to treatment. For children, the dosage is also based on weight. Gabapentin's primary use is to prevent or control seizures. It works by calming down nerve activity to reduce seizure intensity or occurrence. Children and adults can take the drug. Gabapentin is also used in adults to manage a condition called postherpetic neuralgia, which is pain that occurs after shingles. It is not used for routine pain caused by minor injuries or arthritis. Gabapentin is an anticonvulsant.

The market study is being classified and major geographies with country level break-up.

Pfizer (United States), GSK (United Kingdom), Jiangsu Enhua (China), Jiangsu Hengrui (China), Novartis (Switzerland), Actavis (United States) and Glenmark (India) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gabapentin market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Gabapentin market by Type, Application and Region.

On the basis of geography, the market of Gabapentin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Number of Adult Populations
  • Rising Application in Restless Legs Syndrome

Market Trend
  • High Adoption Due to use in Restless Legs Syndrome
  • Rising Demand to Treat Nerve Pain

Restraints
  • The Increasing Concern Regarding Side Effects Of the Gabapentin

Opportunities
  • The Ongoing Research and Development Activities
  • Increasing Healthcare Expenditure

Challenges
  • Stringent Government Regulation Related to Pharmaceuticals



"FDA is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. FDA is requiring new warnings about the risk of respiratory depression to be added to the prescribing information of the gabapentinoids. FDA has also required the drug manufacturers to conduct clinical trials to further evaluate their abuse potential, particularly in combination with opioids, because misuse and abuse of these products together are increasing, and co-use may increase the risk of respiratory depression."

Key Target Audience
Gabapentin Manufactures, Gabapentin Suppliers, Gabapentin Distributors, Government Regulatory Bodies, Private Research Organizations and Government Research Organizations

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By End Products
  • Capsule
  • Tablet
  • Solution
  • Suspension

By Distribution Channel
  • Online Distribution Channel
  • Offline Distribution Channel

By End Use
  • Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome]
  • Pediatric [Epilepsy]

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Adult Populations
      • 3.2.2. Rising Application in Restless Legs Syndrome
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulation Related to Pharmaceuticals
    • 3.4. Market Trends
      • 3.4.1. High Adoption Due to use in Restless Legs Syndrome
      • 3.4.2. Rising Demand to Treat Nerve Pain
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gabapentin, by End Products, Distribution Channel, End Use and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Gabapentin (Value)
      • 5.2.1. Global Gabapentin by: End Products (Value)
        • 5.2.1.1. Capsule
        • 5.2.1.2. Tablet
        • 5.2.1.3. Solution
        • 5.2.1.4. Suspension
      • 5.2.2. Global Gabapentin by: Distribution Channel (Value)
        • 5.2.2.1. Online Distribution Channel
        • 5.2.2.2. Offline Distribution Channel
      • 5.2.3. Global Gabapentin by: End Use (Value)
        • 5.2.3.1. Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome]
        • 5.2.3.2. Pediatric [Epilepsy]
      • 5.2.4. Global Gabapentin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gabapentin (Volume)
      • 5.3.1. Global Gabapentin by: End Products (Volume)
        • 5.3.1.1. Capsule
        • 5.3.1.2. Tablet
        • 5.3.1.3. Solution
        • 5.3.1.4. Suspension
      • 5.3.2. Global Gabapentin by: Distribution Channel (Volume)
        • 5.3.2.1. Online Distribution Channel
        • 5.3.2.2. Offline Distribution Channel
      • 5.3.3. Global Gabapentin by: End Use (Volume)
        • 5.3.3.1. Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome]
        • 5.3.3.2. Pediatric [Epilepsy]
      • 5.3.4. Global Gabapentin Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Gabapentin (Price)
  • 6. Gabapentin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Jiangsu Enhua (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Jiangsu Hengrui (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Actavis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Glenmark (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Gabapentin Sale, by End Products, Distribution Channel, End Use and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Gabapentin (Value)
      • 7.2.1. Global Gabapentin by: End Products (Value)
        • 7.2.1.1. Capsule
        • 7.2.1.2. Tablet
        • 7.2.1.3. Solution
        • 7.2.1.4. Suspension
      • 7.2.2. Global Gabapentin by: Distribution Channel (Value)
        • 7.2.2.1. Online Distribution Channel
        • 7.2.2.2. Offline Distribution Channel
      • 7.2.3. Global Gabapentin by: End Use (Value)
        • 7.2.3.1. Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome]
        • 7.2.3.2. Pediatric [Epilepsy]
      • 7.2.4. Global Gabapentin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gabapentin (Volume)
      • 7.3.1. Global Gabapentin by: End Products (Volume)
        • 7.3.1.1. Capsule
        • 7.3.1.2. Tablet
        • 7.3.1.3. Solution
        • 7.3.1.4. Suspension
      • 7.3.2. Global Gabapentin by: Distribution Channel (Volume)
        • 7.3.2.1. Online Distribution Channel
        • 7.3.2.2. Offline Distribution Channel
      • 7.3.3. Global Gabapentin by: End Use (Volume)
        • 7.3.3.1. Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome]
        • 7.3.3.2. Pediatric [Epilepsy]
      • 7.3.4. Global Gabapentin Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Gabapentin (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gabapentin: by End Products(USD Million)
  • Table 2. Gabapentin Capsule , by Region USD Million (2013-2018)
  • Table 3. Gabapentin Tablet , by Region USD Million (2013-2018)
  • Table 4. Gabapentin Solution , by Region USD Million (2013-2018)
  • Table 5. Gabapentin Suspension , by Region USD Million (2013-2018)
  • Table 6. Gabapentin: by Distribution Channel(USD Million)
  • Table 7. Gabapentin Online Distribution Channel , by Region USD Million (2013-2018)
  • Table 8. Gabapentin Offline Distribution Channel , by Region USD Million (2013-2018)
  • Table 9. Gabapentin: by End Use(USD Million)
  • Table 10. Gabapentin Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome] , by Region USD Million (2013-2018)
  • Table 11. Gabapentin Pediatric [Epilepsy] , by Region USD Million (2013-2018)
  • Table 12. South America Gabapentin, by Country USD Million (2013-2018)
  • Table 13. South America Gabapentin, by End Products USD Million (2013-2018)
  • Table 14. South America Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 15. South America Gabapentin, by End Use USD Million (2013-2018)
  • Table 16. Brazil Gabapentin, by End Products USD Million (2013-2018)
  • Table 17. Brazil Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 18. Brazil Gabapentin, by End Use USD Million (2013-2018)
  • Table 19. Argentina Gabapentin, by End Products USD Million (2013-2018)
  • Table 20. Argentina Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 21. Argentina Gabapentin, by End Use USD Million (2013-2018)
  • Table 22. Rest of South America Gabapentin, by End Products USD Million (2013-2018)
  • Table 23. Rest of South America Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 24. Rest of South America Gabapentin, by End Use USD Million (2013-2018)
  • Table 25. Asia Pacific Gabapentin, by Country USD Million (2013-2018)
  • Table 26. Asia Pacific Gabapentin, by End Products USD Million (2013-2018)
  • Table 27. Asia Pacific Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 28. Asia Pacific Gabapentin, by End Use USD Million (2013-2018)
  • Table 29. China Gabapentin, by End Products USD Million (2013-2018)
  • Table 30. China Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 31. China Gabapentin, by End Use USD Million (2013-2018)
  • Table 32. Japan Gabapentin, by End Products USD Million (2013-2018)
  • Table 33. Japan Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 34. Japan Gabapentin, by End Use USD Million (2013-2018)
  • Table 35. India Gabapentin, by End Products USD Million (2013-2018)
  • Table 36. India Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 37. India Gabapentin, by End Use USD Million (2013-2018)
  • Table 38. South Korea Gabapentin, by End Products USD Million (2013-2018)
  • Table 39. South Korea Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 40. South Korea Gabapentin, by End Use USD Million (2013-2018)
  • Table 41. Taiwan Gabapentin, by End Products USD Million (2013-2018)
  • Table 42. Taiwan Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 43. Taiwan Gabapentin, by End Use USD Million (2013-2018)
  • Table 44. Australia Gabapentin, by End Products USD Million (2013-2018)
  • Table 45. Australia Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 46. Australia Gabapentin, by End Use USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Gabapentin, by End Products USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Gabapentin, by End Use USD Million (2013-2018)
  • Table 50. Europe Gabapentin, by Country USD Million (2013-2018)
  • Table 51. Europe Gabapentin, by End Products USD Million (2013-2018)
  • Table 52. Europe Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 53. Europe Gabapentin, by End Use USD Million (2013-2018)
  • Table 54. Germany Gabapentin, by End Products USD Million (2013-2018)
  • Table 55. Germany Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 56. Germany Gabapentin, by End Use USD Million (2013-2018)
  • Table 57. France Gabapentin, by End Products USD Million (2013-2018)
  • Table 58. France Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 59. France Gabapentin, by End Use USD Million (2013-2018)
  • Table 60. Italy Gabapentin, by End Products USD Million (2013-2018)
  • Table 61. Italy Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 62. Italy Gabapentin, by End Use USD Million (2013-2018)
  • Table 63. United Kingdom Gabapentin, by End Products USD Million (2013-2018)
  • Table 64. United Kingdom Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 65. United Kingdom Gabapentin, by End Use USD Million (2013-2018)
  • Table 66. Netherlands Gabapentin, by End Products USD Million (2013-2018)
  • Table 67. Netherlands Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 68. Netherlands Gabapentin, by End Use USD Million (2013-2018)
  • Table 69. Rest of Europe Gabapentin, by End Products USD Million (2013-2018)
  • Table 70. Rest of Europe Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 71. Rest of Europe Gabapentin, by End Use USD Million (2013-2018)
  • Table 72. MEA Gabapentin, by Country USD Million (2013-2018)
  • Table 73. MEA Gabapentin, by End Products USD Million (2013-2018)
  • Table 74. MEA Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 75. MEA Gabapentin, by End Use USD Million (2013-2018)
  • Table 76. Middle East Gabapentin, by End Products USD Million (2013-2018)
  • Table 77. Middle East Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 78. Middle East Gabapentin, by End Use USD Million (2013-2018)
  • Table 79. Africa Gabapentin, by End Products USD Million (2013-2018)
  • Table 80. Africa Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 81. Africa Gabapentin, by End Use USD Million (2013-2018)
  • Table 82. North America Gabapentin, by Country USD Million (2013-2018)
  • Table 83. North America Gabapentin, by End Products USD Million (2013-2018)
  • Table 84. North America Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 85. North America Gabapentin, by End Use USD Million (2013-2018)
  • Table 86. United States Gabapentin, by End Products USD Million (2013-2018)
  • Table 87. United States Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 88. United States Gabapentin, by End Use USD Million (2013-2018)
  • Table 89. Canada Gabapentin, by End Products USD Million (2013-2018)
  • Table 90. Canada Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 91. Canada Gabapentin, by End Use USD Million (2013-2018)
  • Table 92. Mexico Gabapentin, by End Products USD Million (2013-2018)
  • Table 93. Mexico Gabapentin, by Distribution Channel USD Million (2013-2018)
  • Table 94. Mexico Gabapentin, by End Use USD Million (2013-2018)
  • Table 95. Gabapentin Sales: by End Products(K Units)
  • Table 96. Gabapentin Sales Capsule , by Region K Units (2013-2018)
  • Table 97. Gabapentin Sales Tablet , by Region K Units (2013-2018)
  • Table 98. Gabapentin Sales Solution , by Region K Units (2013-2018)
  • Table 99. Gabapentin Sales Suspension , by Region K Units (2013-2018)
  • Table 100. Gabapentin Sales: by Distribution Channel(K Units)
  • Table 101. Gabapentin Sales Online Distribution Channel , by Region K Units (2013-2018)
  • Table 102. Gabapentin Sales Offline Distribution Channel , by Region K Units (2013-2018)
  • Table 103. Gabapentin Sales: by End Use(K Units)
  • Table 104. Gabapentin Sales Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome] , by Region K Units (2013-2018)
  • Table 105. Gabapentin Sales Pediatric [Epilepsy] , by Region K Units (2013-2018)
  • Table 106. South America Gabapentin Sales, by Country K Units (2013-2018)
  • Table 107. South America Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 108. South America Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 109. South America Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 110. Brazil Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 111. Brazil Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 112. Brazil Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 113. Argentina Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 114. Argentina Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 115. Argentina Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 116. Rest of South America Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 117. Rest of South America Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 118. Rest of South America Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 119. Asia Pacific Gabapentin Sales, by Country K Units (2013-2018)
  • Table 120. Asia Pacific Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 121. Asia Pacific Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 122. Asia Pacific Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 123. China Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 124. China Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 125. China Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 126. Japan Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 127. Japan Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 128. Japan Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 129. India Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 130. India Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 131. India Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 132. South Korea Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 133. South Korea Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 134. South Korea Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 135. Taiwan Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 136. Taiwan Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 137. Taiwan Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 138. Australia Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 139. Australia Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 140. Australia Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 141. Rest of Asia-Pacific Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 142. Rest of Asia-Pacific Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 143. Rest of Asia-Pacific Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 144. Europe Gabapentin Sales, by Country K Units (2013-2018)
  • Table 145. Europe Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 146. Europe Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 147. Europe Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 148. Germany Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 149. Germany Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 150. Germany Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 151. France Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 152. France Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 153. France Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 154. Italy Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 155. Italy Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 156. Italy Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 157. United Kingdom Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 158. United Kingdom Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 159. United Kingdom Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 160. Netherlands Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 161. Netherlands Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 162. Netherlands Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 163. Rest of Europe Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 164. Rest of Europe Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 165. Rest of Europe Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 166. MEA Gabapentin Sales, by Country K Units (2013-2018)
  • Table 167. MEA Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 168. MEA Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 169. MEA Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 170. Middle East Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 171. Middle East Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 172. Middle East Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 173. Africa Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 174. Africa Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 175. Africa Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 176. North America Gabapentin Sales, by Country K Units (2013-2018)
  • Table 177. North America Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 178. North America Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 179. North America Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 180. United States Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 181. United States Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 182. United States Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 183. Canada Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 184. Canada Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 185. Canada Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 186. Mexico Gabapentin Sales, by End Products K Units (2013-2018)
  • Table 187. Mexico Gabapentin Sales, by Distribution Channel K Units (2013-2018)
  • Table 188. Mexico Gabapentin Sales, by End Use K Units (2013-2018)
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Gabapentin: by End Products(USD Million)
  • Table 197. Gabapentin Capsule , by Region USD Million (2019-2024)
  • Table 198. Gabapentin Tablet , by Region USD Million (2019-2024)
  • Table 199. Gabapentin Solution , by Region USD Million (2019-2024)
  • Table 200. Gabapentin Suspension , by Region USD Million (2019-2024)
  • Table 201. Gabapentin: by Distribution Channel(USD Million)
  • Table 202. Gabapentin Online Distribution Channel , by Region USD Million (2019-2024)
  • Table 203. Gabapentin Offline Distribution Channel , by Region USD Million (2019-2024)
  • Table 204. Gabapentin: by End Use(USD Million)
  • Table 205. Gabapentin Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome] , by Region USD Million (2019-2024)
  • Table 206. Gabapentin Pediatric [Epilepsy] , by Region USD Million (2019-2024)
  • Table 207. South America Gabapentin, by Country USD Million (2019-2024)
  • Table 208. South America Gabapentin, by End Products USD Million (2019-2024)
  • Table 209. South America Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 210. South America Gabapentin, by End Use USD Million (2019-2024)
  • Table 211. Brazil Gabapentin, by End Products USD Million (2019-2024)
  • Table 212. Brazil Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 213. Brazil Gabapentin, by End Use USD Million (2019-2024)
  • Table 214. Argentina Gabapentin, by End Products USD Million (2019-2024)
  • Table 215. Argentina Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 216. Argentina Gabapentin, by End Use USD Million (2019-2024)
  • Table 217. Rest of South America Gabapentin, by End Products USD Million (2019-2024)
  • Table 218. Rest of South America Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 219. Rest of South America Gabapentin, by End Use USD Million (2019-2024)
  • Table 220. Asia Pacific Gabapentin, by Country USD Million (2019-2024)
  • Table 221. Asia Pacific Gabapentin, by End Products USD Million (2019-2024)
  • Table 222. Asia Pacific Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 223. Asia Pacific Gabapentin, by End Use USD Million (2019-2024)
  • Table 224. China Gabapentin, by End Products USD Million (2019-2024)
  • Table 225. China Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 226. China Gabapentin, by End Use USD Million (2019-2024)
  • Table 227. Japan Gabapentin, by End Products USD Million (2019-2024)
  • Table 228. Japan Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 229. Japan Gabapentin, by End Use USD Million (2019-2024)
  • Table 230. India Gabapentin, by End Products USD Million (2019-2024)
  • Table 231. India Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 232. India Gabapentin, by End Use USD Million (2019-2024)
  • Table 233. South Korea Gabapentin, by End Products USD Million (2019-2024)
  • Table 234. South Korea Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 235. South Korea Gabapentin, by End Use USD Million (2019-2024)
  • Table 236. Taiwan Gabapentin, by End Products USD Million (2019-2024)
  • Table 237. Taiwan Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 238. Taiwan Gabapentin, by End Use USD Million (2019-2024)
  • Table 239. Australia Gabapentin, by End Products USD Million (2019-2024)
  • Table 240. Australia Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 241. Australia Gabapentin, by End Use USD Million (2019-2024)
  • Table 242. Rest of Asia-Pacific Gabapentin, by End Products USD Million (2019-2024)
  • Table 243. Rest of Asia-Pacific Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 244. Rest of Asia-Pacific Gabapentin, by End Use USD Million (2019-2024)
  • Table 245. Europe Gabapentin, by Country USD Million (2019-2024)
  • Table 246. Europe Gabapentin, by End Products USD Million (2019-2024)
  • Table 247. Europe Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 248. Europe Gabapentin, by End Use USD Million (2019-2024)
  • Table 249. Germany Gabapentin, by End Products USD Million (2019-2024)
  • Table 250. Germany Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 251. Germany Gabapentin, by End Use USD Million (2019-2024)
  • Table 252. France Gabapentin, by End Products USD Million (2019-2024)
  • Table 253. France Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 254. France Gabapentin, by End Use USD Million (2019-2024)
  • Table 255. Italy Gabapentin, by End Products USD Million (2019-2024)
  • Table 256. Italy Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 257. Italy Gabapentin, by End Use USD Million (2019-2024)
  • Table 258. United Kingdom Gabapentin, by End Products USD Million (2019-2024)
  • Table 259. United Kingdom Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 260. United Kingdom Gabapentin, by End Use USD Million (2019-2024)
  • Table 261. Netherlands Gabapentin, by End Products USD Million (2019-2024)
  • Table 262. Netherlands Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 263. Netherlands Gabapentin, by End Use USD Million (2019-2024)
  • Table 264. Rest of Europe Gabapentin, by End Products USD Million (2019-2024)
  • Table 265. Rest of Europe Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 266. Rest of Europe Gabapentin, by End Use USD Million (2019-2024)
  • Table 267. MEA Gabapentin, by Country USD Million (2019-2024)
  • Table 268. MEA Gabapentin, by End Products USD Million (2019-2024)
  • Table 269. MEA Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 270. MEA Gabapentin, by End Use USD Million (2019-2024)
  • Table 271. Middle East Gabapentin, by End Products USD Million (2019-2024)
  • Table 272. Middle East Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 273. Middle East Gabapentin, by End Use USD Million (2019-2024)
  • Table 274. Africa Gabapentin, by End Products USD Million (2019-2024)
  • Table 275. Africa Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 276. Africa Gabapentin, by End Use USD Million (2019-2024)
  • Table 277. North America Gabapentin, by Country USD Million (2019-2024)
  • Table 278. North America Gabapentin, by End Products USD Million (2019-2024)
  • Table 279. North America Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 280. North America Gabapentin, by End Use USD Million (2019-2024)
  • Table 281. United States Gabapentin, by End Products USD Million (2019-2024)
  • Table 282. United States Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 283. United States Gabapentin, by End Use USD Million (2019-2024)
  • Table 284. Canada Gabapentin, by End Products USD Million (2019-2024)
  • Table 285. Canada Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 286. Canada Gabapentin, by End Use USD Million (2019-2024)
  • Table 287. Mexico Gabapentin, by End Products USD Million (2019-2024)
  • Table 288. Mexico Gabapentin, by Distribution Channel USD Million (2019-2024)
  • Table 289. Mexico Gabapentin, by End Use USD Million (2019-2024)
  • Table 290. Gabapentin Sales: by End Products(K Units)
  • Table 291. Gabapentin Sales Capsule , by Region K Units (2019-2024)
  • Table 292. Gabapentin Sales Tablet , by Region K Units (2019-2024)
  • Table 293. Gabapentin Sales Solution , by Region K Units (2019-2024)
  • Table 294. Gabapentin Sales Suspension , by Region K Units (2019-2024)
  • Table 295. Gabapentin Sales: by Distribution Channel(K Units)
  • Table 296. Gabapentin Sales Online Distribution Channel , by Region K Units (2019-2024)
  • Table 297. Gabapentin Sales Offline Distribution Channel , by Region K Units (2019-2024)
  • Table 298. Gabapentin Sales: by End Use(K Units)
  • Table 299. Gabapentin Sales Adult [Epilepsy, Postherpetic Neuralgia, Restless Legs Syndrome] , by Region K Units (2019-2024)
  • Table 300. Gabapentin Sales Pediatric [Epilepsy] , by Region K Units (2019-2024)
  • Table 301. South America Gabapentin Sales, by Country K Units (2019-2024)
  • Table 302. South America Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 303. South America Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 304. South America Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 305. Brazil Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 306. Brazil Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 307. Brazil Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 308. Argentina Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 309. Argentina Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 310. Argentina Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 311. Rest of South America Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 312. Rest of South America Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 313. Rest of South America Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 314. Asia Pacific Gabapentin Sales, by Country K Units (2019-2024)
  • Table 315. Asia Pacific Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 316. Asia Pacific Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 317. Asia Pacific Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 318. China Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 319. China Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 320. China Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 321. Japan Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 322. Japan Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 323. Japan Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 324. India Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 325. India Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 326. India Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 327. South Korea Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 328. South Korea Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 329. South Korea Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 330. Taiwan Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 331. Taiwan Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 332. Taiwan Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 333. Australia Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 334. Australia Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 335. Australia Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 336. Rest of Asia-Pacific Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 337. Rest of Asia-Pacific Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 338. Rest of Asia-Pacific Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 339. Europe Gabapentin Sales, by Country K Units (2019-2024)
  • Table 340. Europe Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 341. Europe Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 342. Europe Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 343. Germany Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 344. Germany Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 345. Germany Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 346. France Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 347. France Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 348. France Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 349. Italy Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 350. Italy Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 351. Italy Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 352. United Kingdom Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 353. United Kingdom Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 354. United Kingdom Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 355. Netherlands Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 356. Netherlands Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 357. Netherlands Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 358. Rest of Europe Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 359. Rest of Europe Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 360. Rest of Europe Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 361. MEA Gabapentin Sales, by Country K Units (2019-2024)
  • Table 362. MEA Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 363. MEA Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 364. MEA Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 365. Middle East Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 366. Middle East Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 367. Middle East Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 368. Africa Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 369. Africa Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 370. Africa Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 371. North America Gabapentin Sales, by Country K Units (2019-2024)
  • Table 372. North America Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 373. North America Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 374. North America Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 375. United States Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 376. United States Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 377. United States Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 378. Canada Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 379. Canada Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 380. Canada Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 381. Mexico Gabapentin Sales, by End Products K Units (2019-2024)
  • Table 382. Mexico Gabapentin Sales, by Distribution Channel K Units (2019-2024)
  • Table 383. Mexico Gabapentin Sales, by End Use K Units (2019-2024)
  • Table 384. Research Programs/Design for This Report
  • Table 385. Key Data Information from Secondary Sources
  • Table 386. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gabapentin: by End Products USD Million (2013-2018)
  • Figure 5. Global Gabapentin: by Distribution Channel USD Million (2013-2018)
  • Figure 6. Global Gabapentin: by End Use USD Million (2013-2018)
  • Figure 7. South America Gabapentin Share (%), by Country
  • Figure 8. Asia Pacific Gabapentin Share (%), by Country
  • Figure 9. Europe Gabapentin Share (%), by Country
  • Figure 10. MEA Gabapentin Share (%), by Country
  • Figure 11. North America Gabapentin Share (%), by Country
  • Figure 12. Global Gabapentin: by End Products K Units (2013-2018)
  • Figure 13. Global Gabapentin: by Distribution Channel K Units (2013-2018)
  • Figure 14. Global Gabapentin: by End Use K Units (2013-2018)
  • Figure 15. South America Gabapentin Share (%), by Country
  • Figure 16. Asia Pacific Gabapentin Share (%), by Country
  • Figure 17. Europe Gabapentin Share (%), by Country
  • Figure 18. MEA Gabapentin Share (%), by Country
  • Figure 19. North America Gabapentin Share (%), by Country
  • Figure 20. Global Gabapentin share by Players 2018 (%)
  • Figure 21. Global Gabapentin share by Players (Top 3) 2018(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2018
  • Figure 25. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GSK (United Kingdom) Revenue: by Geography 2018
  • Figure 27. Jiangsu Enhua (China) Revenue, Net Income and Gross profit
  • Figure 28. Jiangsu Enhua (China) Revenue: by Geography 2018
  • Figure 29. Jiangsu Hengrui (China) Revenue, Net Income and Gross profit
  • Figure 30. Jiangsu Hengrui (China) Revenue: by Geography 2018
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 33. Actavis (United States) Revenue, Net Income and Gross profit
  • Figure 34. Actavis (United States) Revenue: by Geography 2018
  • Figure 35. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 36. Glenmark (India) Revenue: by Geography 2018
  • Figure 37. Global Gabapentin: by End Products USD Million (2019-2024)
  • Figure 38. Global Gabapentin: by Distribution Channel USD Million (2019-2024)
  • Figure 39. Global Gabapentin: by End Use USD Million (2019-2024)
  • Figure 40. South America Gabapentin Share (%), by Country
  • Figure 41. Asia Pacific Gabapentin Share (%), by Country
  • Figure 42. Europe Gabapentin Share (%), by Country
  • Figure 43. MEA Gabapentin Share (%), by Country
  • Figure 44. North America Gabapentin Share (%), by Country
  • Figure 45. Global Gabapentin: by End Products K Units (2019-2024)
  • Figure 46. Global Gabapentin: by Distribution Channel K Units (2019-2024)
  • Figure 47. Global Gabapentin: by End Use K Units (2019-2024)
  • Figure 48. South America Gabapentin Share (%), by Country
  • Figure 49. Asia Pacific Gabapentin Share (%), by Country
  • Figure 50. Europe Gabapentin Share (%), by Country
  • Figure 51. MEA Gabapentin Share (%), by Country
  • Figure 52. North America Gabapentin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • GSK (United Kingdom)
  • Jiangsu Enhua (China)
  • Jiangsu Hengrui (China)
  • Novartis (Switzerland)
  • Actavis (United States)
  • Glenmark (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation